Choose MOTS-C Vial Size — Dosing Guide for Research Use

Choose MOTS-C Vial Size — Dosing Guide for Research Use

Most researchers approach MOTS-C vial size selection backward. They choose based on price per milligram without calculating whether the volume actually aligns with their dosing schedule. A 10mg vial looks like better value until you realise your protocol calls for 5mg weekly and you're left with 5mg that degrades past the 28-day post-reconstitution window. The honest constraint when you choose MOTS-C vial size isn't cost. It's stability after mixing.

We've worked with hundreds of research labs ordering peptides for mitochondrial function studies. The pattern is consistent: vial size mismatches cause more protocol failures than contamination or improper storage combined.

How do you choose MOTS-C vial size for research protocols?

Choose MOTS-C vial size by matching total peptide content to your protocol duration and dose frequency. A 5mg vial supports 4-week cycles at 1.25mg per administration (twice weekly), while 10mg vials extend to 8 weeks at the same frequency. Reconstituted MOTS-C remains stable for 28 days when refrigerated at 2–8°C. Any vial size exceeding your 28-day consumption window results in peptide waste due to irreversible degradation.

Most guides treat vial selection as a purchasing decision. It's a stability calculation. MOTS-C (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid mitochondrial-derived peptide. Its tertiary structure degrades in aqueous solution faster than many synthetic peptides due to the methionine residue at position 12, which oxidises when exposed to dissolved oxygen. Once you add bacteriostatic water, the 28-day countdown starts whether you use 1mg or 10mg. This article covers the exact dosing math that determines which vial size matches your protocol, how reconstitution volume affects shelf stability, and what preparation mistakes negate peptide activity entirely before the first draw.

Why Vial Size Determines Protocol Viability

The standard research dose for MOTS-C ranges from 5mg to 15mg weekly, administered as either a single injection or split into two 2.5–7.5mg doses. These aren't arbitrary ranges. They're derived from the doses used in published mitochondrial function studies where MOTS-C demonstrated measurable improvements in insulin sensitivity and metabolic flexibility. When you choose MOTS-C vial size, you're selecting the container that holds enough peptide to complete your intended protocol without exceeding the 28-day post-reconstitution stability window.

A 5mg vial reconstituted with 2mL bacteriostatic water yields a concentration of 2.5mg/mL. If your protocol calls for 5mg weekly (administered as two 2.5mg doses), that vial provides exactly four weeks of material. Stretch beyond four weeks and you're injecting degraded peptide. The methionine oxidation that begins immediately upon reconstitution accelerates after day 21, and by day 35 the remaining solution contains significantly reduced bioactive MOTS-C even if stored correctly at 2–8°C.

The 10mg vial extends this timeline but introduces a new constraint: concentration management. Reconstitute 10mg in 2mL and you've doubled the concentration to 5mg/mL. Which means smaller draw volumes per dose but tighter measurement precision required. Reconstitute in 4mL and you maintain 2.5mg/mL but now you're storing a larger volume that occupies more refrigerator space and presents a larger surface area for potential contamination during repeated draws. Vial size isn't just about total peptide content. It's about whether the reconstitution math produces a concentration your measurement tools can handle accurately.

Reconstitution Volume and Stability Trade-Offs

MOTS-C stability in solution is concentration-dependent. Higher concentrations (5mg/mL or above) experience slower oxidative degradation per unit volume because there's less dissolved oxygen per milligram of peptide. Lower concentrations (1mg/mL or below) degrade faster because the peptide-to-water ratio drops and each molecule encounters more oxidative stress. The ideal reconstitution zone sits between 2mg/mL and 5mg/mL. Concentrated enough to slow oxidation, dilute enough to allow precise measurement with standard insulin syringes.

When you choose MOTS-C vial size, you're also choosing your reconstitution flexibility. A 5mg vial gives you two practical options: 2mL (yielding 2.5mg/mL) or 1mL (yielding 5mg/mL). The 2mL option is easier to measure. Each 0.5mL draw delivers 1.25mg. But requires more refrigerator space. The 1mL option is compact but demands sub-0.5mL draw precision, which standard 1mL syringes struggle with below the 0.25mL mark.

A 10mg vial opens more combinations: 2mL (5mg/mL), 3mL (3.33mg/mL), or 4mL (2.5mg/mL). The 4mL option mirrors the 5mg vial's concentration but doubles the usable protocol length to eight weeks at 5mg weekly dosing. The trade-off is storage logistics. A 10mL vial holding 4mL of reconstituted solution takes up significantly more space than a 5mL vial holding 2mL, and every additional milliliter increases the risk of introducing air bubbles or contaminants during repeated draws over the extended timeline.

Dosing Frequency Match and Waste Calculation

Research protocols using MOTS-C typically follow one of three frequency patterns: twice weekly (e.g., Monday/Thursday), three times weekly (Monday/Wednesday/Friday), or daily microdosing. Each pattern creates different vial size requirements. Twice-weekly protocols at 5mg total weekly (2.5mg per injection) consume 10mg over four weeks. Meaning a single 10mg vial or two 5mg vials both work without waste. Three-times-weekly protocols at the same total weekly dose (approximately 1.67mg per injection) create awkward draw math that favours 10mg vials reconstituted to 3.33mg/mL.

Daily microdosing. Typically 0.5–1mg per day. Requires the most careful vial size selection. A 5mg vial supports 5–10 days at 0.5–1mg daily, forcing frequent reorders. A 10mg vial extends this to 10–20 days but still falls short of the 28-day stability window, meaning you're either wasting peptide or accepting degraded material toward the end. For daily protocols, our team at Real Peptides typically recommends the 10mg vial with 4mL reconstitution (2.5mg/mL) and acceptance that days 21–28 represent the tail end of peak stability.

Waste isn't just unused peptide. It's the portion that degrades before you can use it. Calculate waste by comparing your protocol's total consumption against the vial's total content within the 28-day window. A 10mg vial used in a twice-weekly 5mg protocol (10mg consumed over four weeks) has zero waste. The same vial used in a once-weekly 7.5mg protocol (7.5mg consumed over four weeks) leaves 2.5mg unused. That's 25% waste regardless of storage precision.

Key Takeaways

MOTS-C remains stable for 28 days post-reconstitution when refrigerated at 2–8°C. Vial size selection must account for total consumption within this window to avoid peptide waste

A 5mg vial supports four weeks at 5mg total weekly dosing (twice weekly at 2.5mg per injection) when reconstituted to 2.5mg/mL in 2mL bacteriostatic water

A 10mg vial extends protocol length to eight weeks at the same 5mg weekly dosing or accommodates higher-frequency protocols (three times weekly) without reconstitution math complications

Reconstitution concentrations between 2mg/mL and 5mg/mL balance oxidative stability with measurement precision. Concentrations below 1mg/mL degrade faster; concentrations above 5mg/mL require sub-0.5mL draw accuracy

Methionine oxidation at position 12 in the MOTS-C peptide sequence accelerates after day 21 post-reconstitution even under ideal storage. Protocols extending beyond four weeks should use 10mg vials to minimise per-vial reconstitution cycles

Daily microdosing protocols (0.5–1mg per day) inherently waste peptide because total 28-day consumption (14–28mg) exceeds single-vial capacities. Accept 10–20% waste or switch to twice-weekly dosing

MOTS-C Vial Size Comparison

The following table compares the three most common vial sizes used in research protocols, showing how each aligns with different dosing frequencies and protocol durations.

5mg

2mL bacteriostatic water

2.5mg/mL

4 doses (2.5mg each)

4 weeks

0% (full vial consumed)

Short research cycles, first-time MOTS-C protocols, labs with limited refrigeration space

Ideal for standard 4-week research blocks. Zero waste if protocol stays on schedule

10mg

4mL bacteriostatic water

8 doses (2.5mg each)

8 weeks

Extended research cycles, higher-frequency dosing (3x weekly), labs running concurrent studies

Best value for continuous research. Same concentration as 5mg vial but doubles usable timeline

5mg/mL

8 doses (2.5mg each, requires 0.5mL draws)

Space-constrained storage, researchers comfortable with sub-0.5mL syringe precision

Most compact option but demands measurement precision. Small draw volume errors compound across doses

What If: MOTS-C Vial Size Scenarios

What If I'm Running a 6-Week Research Protocol?

Use a 10mg vial reconstituted to 2.5mg/mL in 4mL bacteriostatic water. A 5mg vial only covers four weeks at 5mg weekly dosing, forcing you to reconstitute a second vial mid-protocol. Which introduces an unnecessary contamination risk and doubles your reconstitution labour. The 10mg vial provides six weeks of material (7.5mg consumed) with 2.5mg remaining at the end, representing 25% waste. That's acceptable compared to the protocol disruption of mid-cycle vial changeover.

What If My Protocol Calls for 7.5mg Weekly Instead of 5mg?

A 5mg vial becomes non-viable. It only supports a single week plus partial second-week dosing before depletion. Switch to a 10mg vial. At 7.5mg weekly, the 10mg vial supports approximately 10 days of dosing (one full week plus three days), which still falls short of the four-week ideal but reduces the number of vials you'll reconstitute over a month-long study. For 7.5mg weekly protocols extending beyond two weeks, we've found that ordering multiple 10mg vials and staggering reconstitution dates (reconstitute vial 2 on day 14, vial 3 on day 28) keeps you within the 28-day stability window without gaps.

What If I Want to Stockpile Unreconstituted Vials?

Lyophilised MOTS-C stored at −20°C remains stable for 24–36 months in sealed vials. Stockpiling unreconstituted peptide is far more viable than attempting to store reconstituted solution long-term. Order 10mg vials in quantity (three to six vials depending on research timeline) and reconstitute one vial at a time as needed. This approach eliminates the 28-day post-reconstitution constraint and allows you to choose MOTS-C vial size based purely on per-protocol consumption rather than total anticipated use across multiple months.

What If I Accidentally Reconstituted Too Much Volume?

You've diluted the peptide below the ideal 2mg/mL stability threshold. Which accelerates oxidative degradation. If you reconstituted a 5mg vial with 4mL instead of 2mL (yielding 1.25mg/mL instead of 2.5mg/mL), the peptide will degrade noticeably faster after day 14. Don't attempt to re-concentrate by evaporation. That introduces contamination risk and denatures the peptide structure. Use the diluted solution within 21 days maximum and adjust your next reconstitution to the correct volume.

The Blunt Truth About MOTS-C Vial Economics

Here's what most peptide suppliers won't tell you outright: the price-per-milligram comparison between 5mg and 10mg vials is almost meaningless if you're wasting 20–30% of the larger vial due to protocol mismatch. A 10mg vial at $180 ($18/mg) looks cheaper than two 5mg vials at $110 each ($220 total, $22/mg). Until you realise your 5mg weekly protocol leaves 3–4mg unused in the 10mg vial because it degrades past day 28. At that point you paid $18/mg but only used $12/mg worth, making the effective cost $24/mg after accounting for waste.

The vial size decision isn't about finding the lowest sticker price. It's about matching the peptide quantity to your actual consumption within the stability window. Our experience across hundreds of research orders at Real Peptides shows that researchers who choose MOTS-C vial size based on protocol math rather than per-milligram cost consistently report better outcomes. Not because the peptide is chemically different, but because they're using fresh material throughout the entire study instead of degraded solution in the final week.

If your protocol genuinely consumes 10mg within 28 days, buy the 10mg vial. If it consumes 5–7mg, buy the 5mg vial and accept the slightly higher per-milligram cost. The worst decision is buying the 10mg vial

Frequently Asked Questions

Research protocols typically use 5mg to 15mg of MOTS-C weekly, administered either as a single weekly injection or split into two to three smaller doses throughout the week. The 5mg weekly dose represents the lower threshold used in metabolic flexibility studies, while 15mg weekly reflects the upper range explored in insulin sensitivity research. Dose selection depends on the specific research objectives and the metabolic parameters being measured.

Reconstituted MOTS-C remains stable for 28 days when stored at 2–8°C in bacteriostatic water. Stability begins declining after day 21 due to methionine oxidation at position 12 in the peptide sequence — this oxidation accelerates in aqueous solution regardless of storage precision. Freezing reconstituted MOTS-C is not recommended as ice crystal formation physically damages the peptide structure. Unreconstituted lyophilised MOTS-C stored at −20°C remains stable for 24–36 months.

Yes, but you’ll waste 50% of the peptide content. A 10mg vial used in a 5mg-total protocol leaves 5mg unused at the end of four weeks — and since reconstituted MOTS-C degrades significantly after 28 days, that remaining 5mg represents unusable material. The better approach for short protocols consuming 5–7mg total is to choose a 5mg MOTS-C vial size matched to your actual consumption, accepting the slightly higher per-milligram cost in exchange for zero waste.

The ideal reconstitution concentration for MOTS-C sits between 2mg/mL and 5mg/mL. Concentrations in this range balance oxidative stability (higher concentrations slow degradation) with measurement precision (lower concentrations allow easier dose calculation with standard syringes). A 5mg vial reconstituted in 2mL bacteriostatic water yields 2.5mg/mL — this concentration allows precise 0.5mL draws for 1.25mg doses using standard 1mL insulin syringes without requiring sub-0.25mL measurement accuracy.

MOTS-C is a mitochondrial-derived peptide encoded by the 12S rRNA gene in mitochondrial DNA, while SS-31 (elamipretide) is a synthetic tetrapeptide and humanin is encoded by the 16S rRNA region. MOTS-C specifically targets skeletal muscle metabolism and has demonstrated insulin-sensitising effects in published research, whereas SS-31 primarily acts as a cardiolipin-binding antioxidant and humanin shows broader cytoprotective activity. The peptides work through different mechanisms — MOTS-C activates AMPK signalling and influences nuclear gene expression, SS-31 stabilises mitochondrial membranes, and humanin binds to cell surface receptors to trigger anti-apoptotic pathways.

Daily dosing protocols (0.5–1mg per day) inherently create peptide waste because total 28-day consumption (14–28mg) exceeds practical single-vial capacities. A 10mg vial reconstituted to 2.5mg/mL supports 10–20 days of daily dosing depending on dose — meaning you’ll need at least two vials per month and accept 10–20% waste in the final vial. Alternatively, consider switching to a twice-weekly dosing schedule at equivalent weekly totals (e.g., two 3.5mg doses instead of seven 1mg daily doses), which eliminates waste while maintaining similar cumulative peptide exposure.

No. Mixing different peptides in the same vial creates unpredictable interactions that can alter stability, potency, or bioactivity of both compounds. MOTS-C should be reconstituted and stored separately from other research peptides. If your protocol requires administering multiple peptides, prepare each in its own vial and draw doses separately — you can administer them in sequence during the same session, but they must not be pre-mixed in solution.

Vial size offerings reflect different target markets and manufacturing batch economics. 2mg vials serve researchers conducting pilot studies or dose-response experiments where small quantities across multiple concentration points are needed. 5mg and 10mg vials target ongoing research protocols where consistent dosing over multiple weeks is required. Smaller vials (2mg) carry higher per-milligram costs due to packaging and QC overhead but reduce waste for exploratory work — larger vials (10mg) offer better per-milligram economics but require commitment to protocols that consume the full vial within 28 days post-reconstitution.

Unopened lyophilised MOTS-C stored at −20°C maintains stability for 24–36 months from the synthesis date. Peptide degradation in lyophilised form is extremely slow because the absence of water prevents hydrolysis and oxidation reactions. Once removed from freezer storage, unopened vials can tolerate brief ambient temperature exposure (up to 25°C for 48–72 hours) during shipping without significant degradation — but extended room-temperature storage accelerates breakdown and should be avoided. Always verify the synthesis date on the vial label and prioritise using older inventory first when maintaining stockpiles.

Running out of MOTS-C mid-protocol forces you to either halt the study temporarily (introducing a dosing gap that may affect results) or reconstitute a new vial immediately and resume dosing. If you choose to continue, document the gap duration and consider it a protocol deviation that may require statistical adjustment during analysis. The better approach is to calculate total peptide requirements before starting — multiply your per-dose amount by the number of planned administrations, add 10% buffer for measurement variance, and choose the vial size that covers that total within a single 28-day reconstitution cycle or plan for scheduled mid-protocol vial changeover.